Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ01MP)

Drug Name

ILV-095 Drug Info

Synonyms

PF-05212368, WAY-264095

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin-22 (IL22)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fezakinumab	DMJX2P4	Psoriasis vulgaris	EA90	Phase 2	[2]
RG7880	DM452RF	Diabetic foot ulcer	BD54	Phase 2	[3]
F-652	DM9201K	Graft-versus-host disease	4B24	Phase 2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT01010542) Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects. U.S. National Institutes of Health.
2	Emerging Therapies for the Treatment of Psoriasis. Dermatol Ther (Heidelb) 2012 December; 2(1): 16.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis. Hepatology. 2020 Aug;72(2):441-453.